Revenue From Contract With Customer, Initial Research Term

No definition available.

Name:	jnce_RevenueFromContractWithCustomerInitialResearchTerm
Namespace Prefix:	jnce_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Revenue From Contract With Customer, Number of Deliverables

+ References

No definition available.

+ Details

Name:	jnce_RevenueFromContractWithCustomerNumberofDeliverables
Namespace Prefix:	jnce_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Revenue From Contract With Customer, Number of Early-Stage Programs

+ References

No definition available.

+ Details

Name:	jnce_RevenueFromContractWithCustomerNumberofEarlyStagePrograms
Namespace Prefix:	jnce_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Revenue From Contract With Customer, Potential Addition to Research Term

+ References

No definition available.

+ Details

Name:	jnce_RevenueFromContractWithCustomerPotentialAdditiontoResearchTerm
Namespace Prefix:	jnce_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Revenue From Contract With Customer, Potential Aggregate Clinical And Regulatory Milestone Revenue

+ References

No definition available.

+ Details

Name:	jnce_RevenueFromContractWithCustomerPotentialAggregateClinicalAndRegulatoryMilestoneRevenue
Namespace Prefix:	jnce_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Revenue From Contract With Customer, Potential Sales Milestone Revenue

+ References

No definition available.

+ Details

Name:	jnce_RevenueFromContractWithCustomerPotentialSalesMilestoneRevenue
Namespace Prefix:	jnce_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Temporary Equity, Stock Issued During Period, Shares, New Issues

+ References

No definition available.

+ Details

Name:	jnce_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues
Namespace Prefix:	jnce_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	duration

- Definition

Upfront Payment Received

+ References

No definition available.

+ Details

Name:	jnce_UpfrontPaymentReceived
Namespace Prefix:	jnce_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount of revenue, fees and commissions earned from transactions between (a) a parent company and its subsidiaries; (b) subsidiaries of a common parent; (c) an entity and trusts for the benefit of employees, for example, but not limited to, pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management; (d) an entity and its principal, owners, management, or members of their immediate families; and (e) affiliates.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 946
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07.1(c))
-URI http://asc.fasb.org/extlink&oid=116637345&loc=SL114874292-224272

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.1(e))
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227

+ Details

Name:	us-gaap_RevenueFromRelatedParties
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Number of shares issued during the period as a result of the conversion of convertible securities.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29-30)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644

+ Details

Name:	us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
Namespace Prefix:	us-gaap_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	duration

- Definition

Value of new stock classified as temporary equity issued during the period.

+ References

No definition available.

+ Details

Name:	us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Details

Name:	srt_CounterpartyNameAxis=jnce_CelgeneCorporationMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RelatedPartyTransactionAxis=jnce_CelgeneCollaborationAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=jnce_CelgeneLicenseAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_StatementClassOfStockAxis=jnce_SeriesB1PreferredStockMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Celgene Agreements - Narrative (Details) $ in Thousands			1 Months Ended	3 Months Ended
Celgene Agreements - Narrative (Details) $ in Thousands	Jul. 22, 2019 USD ($)	Feb. 01, 2017 shares	Jul. 31, 2016 USD ($) deliverable customer_program shares	Mar. 31, 2020 USD ($)	Sep. 30, 2019 USD ($)	Mar. 31, 2019 USD ($)
Research and Development Arrangement, Contract to Perform for Others [Line Items]
License and collaboration revenue—related party				$ 0		$ 10,981
Celgene Corporation \| Common Stock \| Celgene Collaboration Agreement \| IPO
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Stock converted upon completion of IPO (in shares) \| shares		2,831,463
Celgene License Agreement
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Non-refundable upfront payment received for research agreement	$ 50,000
Aggregate revenue for clinical and regulatory milestones	180,000
Aggregate revenue for sales milestones	$ 300,000
License and collaboration revenue—related party					$ 50,000
Celegene Collaborative Arrangement
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Non-refundable upfront payment received for research agreement			$ 225,000
License and collaboration revenue—related party						$ 11,000
Number of early-stage programs \| customer_program			4
Initial research term			4 years
Potential addition to research term			3 years
Number of program options \| deliverable			6
Celegene Collaborative Arrangement \| Convertible preferred stock (Series B-1)
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Issuances of convertible preferred stock			$ 36,100
Issuances of convertible preferred stock (in shares) \| shares			10,448,100
Celegene Collaborative Arrangement \| Celgene Corporation \| Celgene Collaboration Agreement
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Non-refundable upfront payment received for research agreement			$ 225,000
Celegene Collaborative Arrangement \| Celgene Corporation \| Convertible preferred stock (Series B-1) \| Celgene Collaboration Agreement
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Issuances of convertible preferred stock			$ 36,100
Issuances of convertible preferred stock (in shares) \| shares			10,448,100